DSLT- Dr. Shamik Bafna
At #CaribbeanEye, Dr. Shamik Bafna (@ClevelandEyeClinic) introduced DSLT (Direct Selective Laser Trabeculoplasty)—a revolutionary leap in laser glaucoma treatment! 🌟 🔹 From SLT to DSLT: SLT has been around for 25+ years, but the LiGHT Trial showed it should be a first-line treatment over drops. Now, DSLT takes it to the next level! 🔹 Ultra-Fast & Automated: 120 laser applications in just 3 seconds—compared to conventional SLT, which takes 3-4 minutes. 🔹 No Contact, More Comfort: Unlike traditional SLT, DSLT doesn’t require a contact lens on the eye, making it more comfortable for patients. 🔹 Ergonomic & Efficient: Physicians benefit too—just position the patient, let the eye tracker and limbus tracker do the work, and deliver precise treatment in seconds. 🔹 Accessible & Insurance-Covered: Like SLT, DSLT is typically covered by insurance, minimizing out-of-pocket costs for patients. Is DSLT the future of glaucoma care? Drop your thoughts below! ⬇️ #DSLT #Glaucoma #SLT #Ophthalmology #Innovation #EyeCare Financial Disclosures: Dr. Bafna is a consultant for Alcon References: Wiley W, Bafna S. Early DSLT experience. Presented at: Caribbean Eye Meeting; February 2, 2025; Los Cabos, MX Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, Hunter R, Bunce C, Nathwani N, Barton K; LiGHT Trial Study Group. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension. Ophthalmology. 2023 Feb;130(2):139-151. doi: 10.1016/j.ophtha.2022.09.009. Epub 2022 Sep 17. PMID: 36122660.
